Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,031 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo 400 mg Clear all
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Verekitug, Placebo
Drug · Other
Lead sponsor
Upstream Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Bakersfield, California • Encino, California • Lomita, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

NCT01399008
View directory record Official record
Conditions
Gout
Interventions
Arhalofenate, Allopurinol, Colchicine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
16
States / cities
Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193
View directory record Official record
Conditions
Healthy Subjects
Interventions
Venlafaxine, Moxifloxacin, Drug - placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 5, 2026, 2:39 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 5, 2026, 2:39 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

NCT01198626
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia (CABP)
Interventions
JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)

NCT00063635
View directory record Official record
Conditions
Fatty Liver
Interventions
Metformin, Vitamin E, Matching placebo
Drug · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Sep 5, 2026, 2:39 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

NCT01805791
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
HMPL-004 1800 mg/day, Placebo, HMPL-004 2400 mg/day
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Agawam, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

NCT00582660
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Carcinoma
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

NCT01215747
View directory record Official record
Conditions
Amyloidosis
Interventions
KIACTA (eprodisate disodium), Placebo
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Glendale, California • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

NCT04369391
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856 150 mg, Placebo, moxifloxacin 400 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Little Rock, Arkansas • Long Beach, California • Pico Rivera, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

NCT02777931
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
NFC-1, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 5, 2026, 2:39 AM EDT
Terminated Phase 2 Interventional Results available

MemoryXL Effects on Mild Cognitive Impairment Patients

NCT00903695
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Memory XL, placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

NCT00863746
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Fayetteville, Arkansas • Stanford, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 5, 2026, 2:39 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol in Sickle Cell Disease

NCT06930703
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 4 Interventional Results available

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine

NCT01118273
View directory record Official record
Conditions
Sleep
Interventions
Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 440 mg (BAYH6689), Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 220 mg (BAYH6689), DPH 50mg, Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 5, 2026, 2:39 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

NCT03812380
View directory record Official record
Conditions
Osteoporosis, Hypomagnesemia
Interventions
EffCaMgCit, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

NCT04911127
View directory record Official record
Conditions
Rheumatoid Arthritis, Cannabis
Interventions
200mg Cannabidiol by capsules twice daily, 400mg Cannabidiol by capsules twice daily, Placebo capsules
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 5, 2026, 2:39 AM EDT
Enrolling by invitation Phase 2 Interventional

Chronic Exogenous Ketosis in HFpEF

NCT06937320
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
Interventions
Exogenous Ketone Drink, Placebo
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, overencapsulated caffeine, technetium, placebo
Drug · Radiation
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

NCT02709109
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 5, 2026, 2:39 AM EDT
Not listed Phase 4 Interventional

Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease

NCT04429867
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
WellStar Health System
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia

NCT00596011
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 5, 2026, 2:39 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

NCT02204371
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 5, 2026, 2:39 AM EDT